146 related articles for article (PubMed ID: 30601319)
1. Clinical and economic implications of therapeutic switching of angiotensin receptor blockers to angiotensin-converting enzyme inhibitors: a population-based study.
Kurdi AIB; Elliott RA; Chen LC
J Hypertens; 2019 Jun; 37(6):1285-1293. PubMed ID: 30601319
[TBL] [Abstract][Full Text] [Related]
2. The impact of the 'Better Care Better Value' prescribing policy on the utilisation of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for treating hypertension in the UK primary care setting: longitudinal quasi-experimental design.
Baker A; Chen LC; Elliott RA; Godman B
BMC Health Serv Res; 2015 Sep; 15():367. PubMed ID: 26359265
[TBL] [Abstract][Full Text] [Related]
3. Health outcomes and economic consequences of using angiotensin-converting enzyme inhibitors in comparison with angiotensin receptor blockers in the treatment of arterial hypertension in the contemporary Polish setting.
Wrona W; Budka K; Filipiak KJ; Niewada M; Wojtyniak B; Zdrojewski T
Kardiol Pol; 2016; 74(9):1016-24. PubMed ID: 27112942
[TBL] [Abstract][Full Text] [Related]
4. Effects of a step-therapy program for angiotensin receptor blockers on antihypertensive medication utilization patterns and cost of drug therapy.
Yokoyama K; Yang W; Preblick R; Frech-Tamas F
J Manag Care Pharm; 2007 Apr; 13(3):235-44. PubMed ID: 17407390
[TBL] [Abstract][Full Text] [Related]
5. A Pharmacist Telephone Intervention to Identify Adherence Barriers and Improve Adherence Among Nonadherent Patients with Comorbid Hypertension and Diabetes in a Medicare Advantage Plan.
Abughosh SM; Wang X; Serna O; Henges C; Masilamani S; Essien EJ; Chung N; Fleming M
J Manag Care Spec Pharm; 2016 Jan; 22(1):63-73. PubMed ID: 27015053
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin converting enzyme inhibitors v. angiotensin receptor blockers in the management of hypertension: a funder's perspective.
Makkink JL; Greeff OB
S Afr Med J; 2014 Apr; 104(4):292-4. PubMed ID: 25118555
[TBL] [Abstract][Full Text] [Related]
7. Impact of drug price adjustments on utilization of and expenditures on angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in Taiwan.
Huang SH; Hsu CN; Yu SH; Cham TM
BMC Public Health; 2012 May; 12():288. PubMed ID: 22521158
[TBL] [Abstract][Full Text] [Related]
8. Potential Medicare Savings From Generic Substitution and Therapeutic Interchange of ACE Inhibitors and Angiotensin-II-Receptor Blockers.
Growdon ME; Sacks CA; Kesselheim AS; Avorn J
JAMA Intern Med; 2019 Dec; 179(12):1712-1714. PubMed ID: 31380893
[TBL] [Abstract][Full Text] [Related]
9. Nonadherence to angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers among high-risk patients with diabetes in Medicare Part D programs.
Yang Y; Thumula V; Pace PF; Banahan BF; Wilkin NE; Lobb WB
J Am Pharm Assoc (2003); 2010; 50(4):527-31. PubMed ID: 20621872
[TBL] [Abstract][Full Text] [Related]
10. Updates on the treatment of essential hypertension: a summary of AHRQ's comparative effectiveness review of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and direct renin inhibitors.
Powers B; Greene L; Balfe LM
J Manag Care Pharm; 2011 Oct; 17(8 Suppl):S1-14. PubMed ID: 22088101
[TBL] [Abstract][Full Text] [Related]
11. Angiotensin Receptor Blockers Versus Angiotensin Converting Enzyme Inhibitors for the Treatment of Arterial Hypertension and the Role of Olmesartan.
Omboni S; Volpe M
Adv Ther; 2019 Feb; 36(2):278-297. PubMed ID: 30591990
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers reduced dementia risk in patients with diabetes mellitus and hypertension.
Kuan YC; Huang KW; Yen DJ; Hu CJ; Lin CL; Kao CH
Int J Cardiol; 2016 Oct; 220():462-6. PubMed ID: 27390970
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness Analyses of Antihypertensive Medicines: A Systematic Review.
Park C; Wang G; Durthaler JM; Fang J
Am J Prev Med; 2017 Dec; 53(6S2):S131-S142. PubMed ID: 29153114
[TBL] [Abstract][Full Text] [Related]
14. Retrospective analysis of real-world efficacy of angiotensin receptor blockers versus other classes of antihypertensive agents in blood pressure management.
Petrella R; Michailidis P
Clin Ther; 2011 Sep; 33(9):1190-203. PubMed ID: 21885126
[TBL] [Abstract][Full Text] [Related]
15. Role of antihypertensive therapy with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in combination with calcium channel blockers for stroke prevention.
Talbert RL
J Am Pharm Assoc (2003); 2010; 50(5):e116-25. PubMed ID: 20833609
[TBL] [Abstract][Full Text] [Related]
16. Patterns of prescription antihypertensive drug utilization and adherence to treatment guidelines in the city of Novi Sad.
Tomas A; Tomić Z; Milijasević B; Ban M; Horvat O; Vukmirović S; Sabo A
Vojnosanit Pregl; 2016 Jun; 73(6):531-7. PubMed ID: 27498444
[TBL] [Abstract][Full Text] [Related]
17. Angiotensin converting enzyme inhibitors and angiotensin receptor blockers in the treatment of hypertension: should they be used together?
Verdecchia P; Angeli F; Mazzotta G; Ambrosio G; Reboldi G
Curr Vasc Pharmacol; 2010 Nov; 8(6):742-6. PubMed ID: 20626343
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin axis antagonists increase the incidence of haemodynamic instability in dihydropyridine calcium channel blocker poisoning.
Huang J; Buckley NA; Isoardi KZ; Chiew AL; Isbister GK; Cairns R; Brown JA; Chan BS
Clin Toxicol (Phila); 2021 Jun; 59(6):464-471. PubMed ID: 33021397
[TBL] [Abstract][Full Text] [Related]
19. Angiotensin Receptor Blockers as an Alternative to Angiotensin-Converting Enzyme Inhibitors in Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention.
Lim S; Choo EH; Choi IJ; Ihm SH; Kim HY; Ahn Y; Chang K; Jeong MH; Seung KB
J Korean Med Sci; 2019 Nov; 34(45):e289. PubMed ID: 31760711
[TBL] [Abstract][Full Text] [Related]
20. The Incidence and Risk of Biochemical Recurrence Following Radical Radiotherapy for Prostate Cancer in Men on Angiotensin-Converting Enzyme Inhibitors (ACEIs) or Angiotensin Receptor Blockers (ARBs).
Alashkham A; Paterson C; Windsor P; Struthers A; Rauchhaus P; Nabi G
Clin Genitourin Cancer; 2016 Oct; 14(5):398-405. PubMed ID: 27053500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
